β-blockers – Medxy AI

β-Blockers in Post-Myocardial Infarction Patients with Mildly Reduced Ejection Fraction: A Meta-Analysis of Randomized Trials

By MedXY 10/11/2025

This meta-analysis reveals that β-blocker therapy reduces mortality and adverse cardiovascular events in myocardial infarction patients with mildly reduced left ventricular ejection fraction (40–49%), extending benefits beyond reduced LVEF populations.

Cardiology news Specialties

Evaluating β-Blocker Use and Health Status in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial

By MedXY 09/11/2025

This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.